Preoperative window-of-opportunity (WoO) study of Debio 1143 with or without cisplatin (CDDP) in patients with resectable squamous cell carcinoma of the head and neck.
Latest Information Update: 06 Oct 2023
At a glance
- Drugs Xevinapant (Primary) ; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Pharmacodynamics
- Sponsors Debiopharm
- 30 Sep 2023 Results published in the Clinical Pharmacology and Therapeutics
- 02 Apr 2022 Status changed from recruiting to completed.
- 01 Oct 2020 According to a Debiopharm media release, 3-year data from this study were presented at the ESMO (European Society of Medical Oncology) virtual congress